diabetic-macular-edema
(3)
Therini Bio, Inc.
Therini Bio is a clinical-stage biotechnology company developing fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. Founded in 2019 on the neurovascular research of Dr. Katerina Akassoglou at UCSF and the Gladstone Institutes, the company's lead antibody THN391 selectively blocks fibrin's inflammatory epitope to halt chronic neuroinflammation without interfering with normal blood clotting. Backed by roughly $145M in total funding from investors including Eli Lilly, Sanofi Ventures, Merck's MRL Ventures and the Dementia Discovery Fund, Therini is advancing THN391 into Phase 1b trials for Alzheimer's disease and diabetic macular edema.
Jason Ehrlich
Jason Ehrlich is the co-founder and CEO of Ollin Biosciences, an Austin-based clinical-stage biopharma launched in September 2025 with $100 million to build best-in-disease eye medicines. An MD-PhD ophthalmologist trained at Princeton and Stanford, he spent a decade at Genentech/Roche helping shepherd retina drugs including Lucentis and the bispecific faricimab (Vabysmo), then served five years as chief medical and development officer at Kodiak Sciences. At Ollin he is taking direct aim at the market leader: in early 2026 his lead asset OLN324 beat faricimab head-to-head in a randomized Phase 1b study, drying retinas faster and deeper with a clean safety record.
Ollin Biosciences
Ollin Biosciences is an Austin-based clinical-stage biopharmaceutical company building a portfolio of best-in-disease therapies for vision-threatening eye diseases. Founded in 2023 and launched publicly in September 2025 with $100M in Series A financing, Ollin in-licenses validated drug candidates and races them through head-to-head trials against the market leaders. Its lead program, OLN324, is a VEGF/Ang2 bispecific antibody for wet age-related macular degeneration and diabetic macular edema that posted superior anatomic results versus Roche's blockbuster Vabysmo in a Phase 1b study.